Alzheimer's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older, of any gender.
- People who are cognitively normal or have been clinically assessed as having mild dementia.
- People who are able and willing to undergo brain scanning (MRI or CT), a PET scan, an injection of a radioactive tracer, and optionally a lumbar puncture (spinal fluid sample); a CT scan will be used for those unable to have an MRI.
- Women who have not yet gone through menopause will need to take a urine pregnancy test within 24 hours before the study drug is given.
Who may not be able to join:
- People with any condition that, in the investigator's opinion, could increase risk, limit the ability to tolerate the study procedures, or interfere with data collection or analysis (for example, severe chronic back pain that would make lying still during scans difficult).
- People who are considered unlikely to be able to complete the imaging procedures for any reason.
- People who have a high risk of a specific heart rhythm problem called Torsades de Pointes, or who are taking medications known to affect a heart measurement called the QT interval.
- People who have a known allergy or sensitivity to the study tracer F 18 T807 or any of its ingredients.
- People for whom PET, PET-CT, or MRI scanning would be unsafe — for example, those with certain electronic medical devices in their body or who cannot lie still for extended periods.
- People with severe claustrophobia (extreme fear of enclosed spaces).
- People who are currently pregnant or breastfeeding.
- People who wish to take part in the optional lumbar puncture (spinal fluid sample) portion and are currently taking any form of blood-thinning medication (anticoagulants).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Tammie Benzinger, MD, PhD, Washington University School of Medicine
Phone: 314 362-1558
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
F 18 T807 Standard Uptake Value Ratios (SUVR) will be correlated with other imaging modalities (MRI, PET amyloid imaging) and cognitive performance.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.